Race's first important asset is a chemotherapy drug called Bisantrene which was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology has rediscovered Bisantrene and we plan to put this valuable drug back in the hands of clinicians to treat Leukaemia.
In the United States, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete clinical development and gain approval by the US FDA.
Race Oncology CEO Peter Molloy and Chair Dr Bill Garner.
Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed
Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s